Latest Breaking News On - Rattiya thongdumhyu shutterstock - Page 6 : comparemela.com

Researchers manufacture the SARS-CoV-2 RBD in pichia Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). The approach produces the receptor-binding domain (RBD) of the spike protein that the virus uses to bind to and infect host cells. The spike RBD is a primary target of neutralizing antibodies following vaccination or natural infection. The new manufacturing process uses a genetically engineered strain of the microbe Komagataella phaffii (Pichia pastoris) to produce the spike RBD. The use of this microbial host eliminates the need for methanol-induction of the recombinant RBD gene, which can present challenges in large-scale facilities.

United statesUnited kingdomChristopher loveRattiya thongdumhyu shutterstockSally robertsonSerum institute of india pvtMassachusetts institute of technologyRattiya thongdumhyuMassachusetts instituteSerum instituteஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்கிறிஸ்டோபர் காதல்சாலி ராபர்ட்சன்சீரம் நிறுவனம் ஆஃப் இந்தியா பிரைவேட்மாசசூசெட்ஸ் நிறுவனம் ஆஃப் தொழில்நுட்பம்